Necrotizing Enterocolitis
Necrotizing Enterocolitis (NEC) is a severe and life-threatening gastrointestinal disorder primarily affecting premature infants, characterized by intestinal inflammation, bacterial invasion, and progressive bowel necrosis. The disease is associated with substantial neonatal morbidity and mortality and remains one of the most critical emergencies in neonatal intensive care units (NICUs). Early diagnosis and timely intervention are essential to improve survival outcomes and reduce long-term complications.
Necrotizing Enterocolitis Epidemiology Segmentation
<ul>
<li dir="ltr" aria-level="1">
Total Incident Cases of Preterm Infants by Birth Weight (&le;1,500 g)
</li>
<li dir="ltr" aria-level="1">
Total Incident Cases of Necrotizing Enterocolitis
</li>
</ul>
Necrotizing Enterocolitis Epidemiology
<ul>
<li dir="ltr" aria-level="1">
Across the 7 Major Markets (7MM), the total incident population of necrotizing enterocolitis was estimated at approximately 6K cases in 2025.
</li>
<li dir="ltr" aria-level="1">
In the United States alone, the annual incidence of NEC remains within the range of approximately 3,000&ndash;5,000 cases, highlighting the significant burden among premature infants.
</li>
<li dir="ltr" aria-level="1">
Across the 7MM, the population of preterm infants with birth weight &le;1,500 g is expected to remain stable to slightly increasing through 2030, primarily due to improved neonatal survival rates rather than a substantial increase in preterm births.
</li>
<li dir="ltr" aria-level="1">
Prematurity and very low birth weight remain the strongest risk factors for NEC development, with disease burden concentrated within neonatal intensive care settings.
</li>
</ul>
Necrotizing Enterocolitis Market
<ul>
<li dir="ltr" aria-level="1">
Within the 7 Major Markets (7MM), the necrotizing enterocolitis market is expected to expand significantly during the forecast period (2026&ndash;2036), driven by growing awareness, improved neonatal care, and the advancement of pipeline therapies.
</li>
<li dir="ltr" aria-level="1">
The NEC market size across the 7MM was estimated at approximately USD 30 million in 2025.
</li>
<li dir="ltr" aria-level="1">
Pipeline therapies such as IBP-9414 are anticipated to attract considerable market attention due to the absence of approved disease-specific therapies and the high unmet medical need in neonatal care.
</li>
</ul>
Necrotizing Enterocolitis Market Drivers
<ul>
<li dir="ltr" aria-level="1">
The high disease burden among premature and low-birth-weight infants continues to drive demand for improved preventive and therapeutic strategies for NEC.
</li>
<li dir="ltr" aria-level="1">
Increasing focus on preventive neonatal care, microbiome-based interventions, and immunomodulatory approaches is accelerating research and development activities in the NEC landscape.
</li>
<li dir="ltr" aria-level="1">
Growing healthcare expenditure and advancements in neonatal intensive care infrastructure are supporting earlier diagnosis, improved disease management, and broader therapeutic adoption.
</li>
</ul>
Necrotizing Enterocolitis Market Barriers
<ul>
<li dir="ltr" aria-level="1">
Current treatment strategies remain largely supportive and non-targeted, with limited therapeutic innovation over recent decades.
</li>
<li dir="ltr" aria-level="1">
Challenges associated with early and accurate diagnosis of NEC continue to delay timely intervention and contribute to high mortality and complication rates.
</li>
<li dir="ltr" aria-level="1">
Limited research funding and the difficulties associated with conducting clinical trials in neonatal populations may hinder the development and commercialization of novel therapies.
</li>
</ul>
Emerging Necrotizing Enterocolitis Drugs
<ul>
<li dir="ltr" aria-level="1">
IBP-9414
</li>
<li dir="ltr" aria-level="1">
STMC-106
</li>
<li dir="ltr" aria-level="1">
ST266
</li>
<li dir="ltr" aria-level="1">
Protego-PD
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
Key Necrotizing Enterocolitis Companies
<ul>
<li dir="ltr" aria-level="1">
Infant Bacterial Therapeutics
</li>
<li dir="ltr" aria-level="1">
Siolta Therapeutics
</li>
<li dir="ltr" aria-level="1">
Noveome Biotherapeutics
</li>
<li dir="ltr" aria-level="1">
Plakous Therapeutics
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
&nbsp;

Necrotizing Enterocolitis Market Infographics

Explore Necrotizing Enterocolitis market infographics featuring key insights on market trends, disease burden, treatment landscape, pipeline developments, and future growth outlook.